A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 123 participants.

Also called NCT01174160

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 123 participants (enrolled count) (from the registry)
Sponsor
Advanz Pharma (from the registry)
Registry
  • NCT NCT01174160
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01174160. Randomized; double masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2012-09 (actual). Results posted on 2015-12-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)
Intervention (Drug)
vernakalant hydrochloride
Intervention (Drug)
Placebo to vernakalent hydrochloride
Lead sponsor
Advanz Pharma (class: industry)

Record details

Record id
cardio:ct-nct01174160
Content hash
630e1925857db60f85adf9e53e871d5b4b7ff59863251baae27fbe3b5999f843